## Supplementary Table 3. Quantitative results

Study ID	Instrum	Study	Sample	Reported	Deauth
	ent	design	size	format	Result
Bratas 2010	forced choice: treatment	Cross- sectional survey	205	Choice or proportion of choice	A total of 161 patients chose inpatient rehabilitation and 44 chose outpatient clinics. The decision to choose rehabilitation may be determined by impaired health-related quality of life, psychological distress and lack of psychological support from a significant other.
Brophy 2008	forced choice: inhaler	Randomize d controlled trial	25	Choice or proportion of choice	Preference for bronchodilator treatment nebulizer vs MDI and spacer : 15 patients vs 10 patients
Bulcun 2014	Conjoint analysis/Di screte choice	Cross- sectional survey	49		Extent to which the doctor gives sufficient time to listen to the patient RARELY: -1.5 SOMETIME: -0.5
Carlucci 2016	Forced choice: treatment	Cross- sectional study	55	Odds ratio and 95% Cl	OR of choice of NIV as a 'ceiling' treatment for a current use of NIV: OR = 4.93, 95% CI = 1.17–23.54 OR of choice of NIV as a 'ceiling' treatment for a recent family bereavement: OR = 4.77, 95% CI = 1.12–22.95. p = 0.026
Chakrabarti 2009	forced choice: treatment	Cross- sectional survey	50	Choice or proportion of choice	Willingness to accept a IMV during an exacerbation after stage 4: 60% (30/50) willing, 30% (15/50) unwilling.
Chapman 1993	forced choice: inhaler	Cross- sectional survey	80	Choice or proportion of choice	preference for breath actuated device vs conventional MDI: 71.3% vs 18.8% vs 10% no preference MDI familiaar group: 72.5% vs 15% vs 12.5% no preference MDI unfamiliar group: 70% vs 22.5% vs 7.5% no difference
Chapman 2011	forced choice: inhaler	Randomize d controlled trial	82	Choice or proportion of choice	overall preference for Breezehaler vs Handihaler vs no preference: 60.5% vs 30.9% vs 8.6% Remove/open cap: 58.0% vs 19.8% vs 22.2% Open mouthpiece: 64.2% vs 9.9% vs 25.9%
Chen 2016	EQ-5D utility, willingness to pay	Cross- sectional study	142	Mean (SD), Mean (SE)	COPD: 0.84 (0.21) mild COPD: 0.88 (0.20) moderate COPD: 0.89 (0.16) severe COPD: 0.79 (0.20)
Claessens 2000	Forced choice: treatment	Cohort study	1008	Choice or proportion of choice	Preference for treatment focusing on relieving pain and discomfort rather than extending life : 58% Preference for Do Not Resuscitate order : 37% "Very unwilling" or "Would rather die" than be attached to a ventilator "all the time" :
Dal Negro 2016	Forced choice: inhaler	Cross- sectional study	157 (47% of 333 patients had COPD, the rest had	Choice or proportion of choice	preference device C (the Respimat SMI): 47% COPD patients
Dales 1999	Probability trade off	Repeated surveys	20	Choice or proportion of choice	Baseline Choice ventilation Choice After Decision Aid-yes: 5 (71%), strengh of preference for MV (mean): 0.89 Choice After Decision Aid-no: 2 (29%), strengh of preference for MV (mean): 0.01 Baseline Choice no ventilation
Dowson 2004	ranking: treatment	Cross- sectional survey	39	Choice or proportion of choice	<ol> <li>Phone GP or after hours practice 2.6%</li> <li>Take (extra) prednisone 0%</li> </ol>
Fox 1999	Forced choice: treatment	Cross- sectional survey	1016	Choice or proportion of choice	preference for paliative care: 33.6%
Fried 2002	Probability trade off	Cross- sectional survey	81	Choice or proportion of choice	treatment preferences (proportion of wanting the treatment under certain circumstance) SCENARIO 1—LOW BURDEN, RESTORATION OF
Fried 2007	Probability trade off	Repeated surveys	64	Choice or proportion of choice	Willingness to Undergo High-Burden Therapy to Avoid Death: 32 (50%) Willingness to Risk Physical Disability to Avoid Death: 41 (64%) Willingness to Risk Cognitive Disability to Avoid Death: 44 (69%)

					Alignahan of methods.
	Forced	Repeated		Choice or	Number of patients:
Gaber 2004	choice:	-	100	proportion of	Patient's views towards "yes" CPR, IV and NIV: 48
	treatment	surveys		choice	Patient's views towards "yes" IV and NIV: 19
	Willingness			Choice or	Patient's views towards "ves" IV: 10 always usual hospital care: 29 (25%)
Goossens	0	Cross-			always usual hospital care. 29 (25%) always early assisted discharge: 5 (46%)
2014	to pay,	sectional	107	· ·	
2014	Conjoint	survey		choice	Both: 33 (29%)
	analvsis/Di		First survou	Mean	Willingness to pay First survey Preference of Respimat or HandiHaler
Hanada	Forced	Repeated	First survey:	Choice or	
	choice:	-	57	proportion of	Preferring Respimat: 45.6% (Respimat is much better 3.5%; Respimat is better: 42.1%);
2015	treatment	surveys	Second	choice	
		Randomize	survev: 39		Second survey Preference of Respimat or HandiHaler Number of patients
Hansen	Forced			Choice or	
1990	choice:	d	48	proportion of	Patients preferred turbutaline: 23
1990	treatment	controlled		choice	Patients preferred placebo: 9
	VAS,	trial Trial, non-		Median	Patients indicated not difference between treatments: 16 VAS
Hansen					-
	Forced	randomized	25	(Range)	2 weeks after treatment: 67 (1-100) for turbuhaler and 48 (7-99) for pari-inhalier boy
1994	choice:	or non-		Choice or	
	inhaler Conigint	controlled Cross-		proportion of	Number of patients Impact on everyday life
Haughney	Conjoint				
• ·	analysis/Di		125	Mean	Little impact on activities, able to go for a short walk: 7.6;
2005	screte	survey (A			Able to wash and dress and move around the house: 4.4;
	choice	fractional			Able to wash and dress. walking almost impossible : 3 I would participate in a research study even if it was inconvenient for me but it
Hohmeier	patient	Cohort		Choice or	
2016	perception		12	proportion of	concluded with an improvement in my COPD management and improvement in my
2016	survey	study		choice	overall health and quality of life
					strongly agree: 4
Hwang	Forced	Cross-			
2011	choice:	sectional	300		
2011	treatment	survey			
					COPD patients preferring CPR: 70.50%
Janssen	Probability	Cross-		Choice or	COPD patients preferring MV: 70.50%
2011b	trade off	sectional		proportion of	Low-burden
20110	trade on	survey		choice	
			Dutch		likelihood of death 0%: 95.2% Patients' preferences in their current health state for MV: 70.5% of Dutch population
Janssen	Forced	Cross-	patients:	Choice or	and 58.2% of US patients reported they would accept
2011c	choice:	sectional	122	proportion of	Patients' preferences in their current health state for CPR: 69.7% of Dutch and 70.2% of
20110	treatment	survey		choice	US patients
			US patients:		Patients pMDI device difficult to use: 46%
	Forced	Cross-		Choice or	Patients DPI use device difficult to use: 17%
Jarvis 2007	choice:	sectional	53	proportion of	Patients using a pMDI alone felt able to indentify a "clinical benefit": 58%
	inhaler	survey		choice	Patients using a DPI alone felt able to indentify a "clinical benefit": 33%
	Forced				Preference of information
	choice:	Cross-		Choice or	What are all possible side effects of treatment: absolutely want 80 (80.8%); would like
Jordan 2014	Preferences	sectional	44	proportion of	16 (16.2%); do not want 3 (3%)
	of	survey		choice	What effect can I expect from this treatment: absolutely want 85 (85.9%); would like 9
	Willingness				Utility score
Kawata	to pay,	Cross-		Mean (95%	Little or no reliefe (complete relief as reference) : -1.23 (-1.33, -1.12)
2014	Conjoint	sectional	515	CI)	some reliefe (complete relief as reference) : -0.54 (-0.64, -0.43)
2014	analysis/Di	survey		,	Feel medicine start to work within 20 min (within 5 min as reference) : -0.19 (-0.24
		1		a i	preference for Do-Not-Resuscitate (DNR)
Lynn 2000	Forced	Cohort	416 died	Choice or	29% of natients who were long-term survivors
	choice:	study		proportion of	43% of those who survived to leave the hospital but lived less than a year
	treatment	,	enrolled	choice	42% of those who died during the first hospitalization
	<b>F</b>	Randomize		Chu ch	
Mahler	Forced	d		Choice or	Preferences of treatment: Eight patients preferred salmeterol Diskus, seven patients
2014	choice:	controlled	20	proportion of	preferred arformoterol solution, and five patients had no preference.
	treatment	trial		choice	
		u lai			Males and face day, according to the large (2, 200)
		-			Males prefers dry-powdered innalers: 62.30%
Martínez	Forced	Cross-		Choice or	Males prefers dry-powdered inhalers: 62.30% Females prefers dry-powdered inhalers: 54.60%
	Forced choice:	Cross- sectional	568	proportion of	Females prefers dry-powdered inhalers: 54.60%
Martínez 2012			568		Females prefers dry-powdered inhalers: 54 60%

	VAS, EQ-5D	Randomize		Mean (SD),	Telemonitoring with usual care (EQ-5D scores at baseline) 0.49 (0.35)
McDowell	utility,	d		Mean (95%	Usual care (EQ-5D scores at baseline) 0.52 (0.30)
2015	forced	controlled	110	CI), choice or	Telemonitoring with usual care (EQ-5D VAS scores at baseline) 50.1 (18.0)
	choice:	trial		proportion of	
	Forced	Randomize			28 of the 53 participants (53%) indicated the pool as their preferred environment, 23/53
McNamara	choice:	d		Choice or	(43%)the gym and 2/53 (4%) reported no preference for either environment.
2015	place of	controlled	53	proportion of	Of the 18 water-based exercise training participants, 16/18 (89%) indicated they would
	treatment	trial		choice	prefer to continue exercise training in the pool, whilst 2/18 (11%) indicated they would
	Conjoint	Cross-		Mean	I am extremely satisfied with my main inhaler: 5.5
Molimard	analysis/Di		245	Choice or	The three main inhaler attributes that the patients considered to be most important
2005	screte	sectional	245	proportion of	were ease of use/convenience, efficacy, and inhaler size which were given primary
	choice	survey		choice	importance by 66%. 29%. and 27% patients, respectively.
	Forced	Cross-		Choice or	Proportion of patients considering following attributes "very important"
Moore 2004		sectional	256	proportion of	Overall ease of using: 86%
10010 2004	inhaler	survey	250	choice	Being quick to use when you need it: 84%
	IIIIaici	Survey		choice	Ease of holding or gripping: 79%
	Forced	<u> </u>			
Mutterlein	choice:	Cross-over	60		
1990	device	study			
	Forced	Cross-		Choice or	Current health (No ventilation): 39.60%
Norris 2005	choice:	sectional	111	proportion of	Current health (No CPR): 38.40%
	treatment	survey		choice	Permanent coma (No ventilation): 93.60%
		Trial, non-			Permanent coma (No CPR): 91.00% continuation of Onbrez
	Forced	-		Choice or	
Ohno 2014	choice:	randomized	28	proportion of	Definitely want to continue: 2 (7.7%)
	treatment	or non-		choice	Want to continue: 14 (53.8%)
		controlled Randomize			Equivocal: 10 (38.5%) treatment preferences
	Forced	d		Choice or	Sixteen of the 27 patients (59.3%) in the conventional arm and 26 of the 27 (96.3%) in
Ojoo 2002	choice:	u controlled	61	proportion of	the domiciliary arm would have preferred domiciliary management.
	treatment	trial		choice	Thirty four carers completed the guestionnaires and the respective carer preference
Oliver 1997	Ranking: treatment	Cross-over study	20		
	Willingness	Cross	146 patient	Choice or	In making a decision to be screened, screening convenience is important
D-11:- 2012	to pay,	Cross- sectional	approached/		Former smoker: 64%
Pallin 2012	Forced		142	proportion of	Current smoker: 71.4%
	choice:	survey	completed	choice	total: 66.9%
	Forced			Choice or	Proportion of patients preferring Genuair to Breezhaler (after 2 weeks): 72.7% vs. 27.3%
Pascual	choice:	Cross-over	127	proportion of	Willingness to continue using each inhaler (Genuair vs. Breezlaher; on a scale of 0–100):
2015	inhaler	study	127	choice, Mean	79.6 (2.60) vs. 63.6 (2.60)
	IIIIaiei			(SE)	
	Conjoint	Cross-		Choice or	Relative importance of the COPD attributes (%):
Pisa 2013	analysis/Di	sectional	300	proportion of	Total
	screte	survey	500	choice	Dyspnea: 36%
	choice	Survey		choice	Performance capability (bodily resilience) due to COPD: 19%
Price 2013b	Forced	C. h		Choice or	agreement of preference for once-daily therapy
	choice:	Cohort	2138	proportion of	Strongly agree: 12%
	treatment	study	0	choice	Agree: 32.6%
			1202 1		Not sure: 24.9%
Reinke 2011	Forced	Cross-	1292 invited	Choice or	Preferences on CPR
	choice:	sectional	but 376	proportion of	Total: 266 (77.8%)
	treatment	survey	meet the	choice	history of depression: 97 (75.2%)
			inclusion		no history of depression: 169 (79.3%) In the attribute of
	Forced	Randomize		Choice or	
Riley 2016	choice:	d	618	proportion of	"the number of steps" preference for Ellipta™ DPI: 59%, HandiHaler®: 17%, no
	inhaler	controlled		choice	preferences: 24%
		trial	84 (what		"time taken to use" preference for Ellipta™ DPI: 62%. HandiHaler®: 14%. no preference: Therapeutic or care choices affecting you may have to be made during the treatment
	Preferences		•	Choice or	
Rinnenburg	of decision	Repeated	was the	proportion of	(decisions about hospital admission. medical tests. therapies). Would you like to be
er 2012	making	surveys	84% of	choice	involved in the decision making process. alongside doctors. or would you rather
	mode	I	whole		delegate decisions to others?

	Patient's	Randomize			
	expectation			Least	Patient's expectation of treatment adherence
Siler 2014	of	u controlled	40	squares	Indacterol group: 2.1 (0.21) ; placebo 2.3 (0.21)
	-			mean (SEM)	
	treatment	trial			
Stapleton	Forced	Cross-		Choice or	want mechanical ventilation: 62.20%
2005	choice:	sectional	101	proportion of	want CPR: 63.60%
2005	treatment	survey		choice	Walk Crk. 05.00%
	Time trade			Median (95%	SG 0.95 (0.88-0.97) range: 0.05-1
Stavem	off,	Cross-		•	TTO 0.91 (0.70-0.93) range: 0.05-1
2002b	Standard	sectional		, ,	EQ-VAS 0.54 (0.50-0.65) range: 0.05-0.95
20025	gamble.	survey		CI)	
		Randomize			15D 0.80 (0.77-0.83) range: 0.54-1
Sutherland	Forced	d		Choice or	for all participants: 40.3% for IPR-ALB MDI and 50% for FFIS Nebulizer, 9.9% no
2009	choice:	controlled	99/ 109	proportion of	difference; for severe patients: 28.3% for IPR-ALB MDI and 63.0% for FFIS Nebulizer,8.7%
2000	device	trial		choice	no difference
					No (%) of patients expressing preference for the ELLIPTA DPI
Svedsater	Forced	Cross-		Choice or	For patients using DISKUS as comparator device: 18 (86%);
2013	choice:	sectional	42	proportion of	For patients using MDI/HFA as comparator device: 15 (60%);
2015	inhaler	survey		choice	For patients using HandiHaler as comparator device: 17 (85%).
		Randomize			HUI
Torrance	HUI,	d			first AECB Ciprofloxacn: 0.72 (0.20), usual care: 0.68 (0.19)
1999	willingness	controlled	222 in 240		At regular visit no.1 Ciprofloxacn: 0.78 (0.21), usual care: 0.77 (0.19)
1999	to pay			in culur	At regular visit no.2 Ciprofloxacii. 0.78 (0.21), usual care: 0.77 (0.13) At regular visit no.2 Ciprofloxacii: 0.80 (0.20), usual care: 0.78 (0.18)
		trial			
Travaline	Forced	Cross-		Choice or	decision to use MV
1995	choice:	sectional	37	proportion of	yes 15 (40%); no 8 (22%); unsure: 14 (38%)
1999	treatment	survey		choice	yes 19 (10/0), 10 0 (22/0), unsule: 1 (30/0)
	Forced	Randomize			Preference to be treated at home at T+4 days
	choice:	d		Choice or	25(42%) in the usual hospital treatment group and 56 (86%) in the early assisted group
Utens 2013	place of	controlled	139	proportion of	Preference to be treated at home at T+90 days
	treatment	trial		choice	17 (35%) in the usual hospital treatment group and 33 (59%) in the home treatment
	Forced		124 (62		Preference to be treated at home at the end of the 7-day treatment
	choice:	d	caregivers	Choice or	15 (33.3%) of informal caregivers of patients allocated to usual hospital care and 37
Utens 2014	place of	controlled	each in	proportion of	(71.2%) of informal caregivers allocated to hospital-at-home
	treatment	trial	either	choice	Preference to be treated at home at the end of the follow up
	Forced	Randomize	eithei	Mean (SD)	willingness to continue inhaler use (scale 0 = not willing to 100 = definitely willing)
van der	choice:	d		Choice or	84.0 (3.2) for Genuair and 62.5 (3.2) for HandiHaler
Palen 2013a		controlled	129	proportion of	
	willingness	trial		choice	more patients preferred Genuair than HandiHaler (79.1 vs 20.9%: p < 0.0001)
	Forced	Randomize		Choice or	COPD inhaler preference
van der	choice:	d	113, while	proportion of	52 (72.2%) for Diskus, 20 (27.8%) for Elpenhaler
Palen 2013b	inhaler,	controlled	82 for COPD	choice	
	willingness	trial		Mean (SD)	willingness to continue inhaler use (scale 0 = not willing to 100 = definitely willing)
	Forced				patients preferred the ELLIPTA inhaler overall compared with the comparator devices
van der		Cross-over	F (7		(Figure 2). The majority of patients also preferred the ELLIPTA inhaler for most individual
Palen 2016	choice:	study	507	proportion of	criteria (number of steps for correct use, time taken to use, size of the device, dose
	inhaler			choice	counter. comfort of mouthpiece and ease of opening: Po0.001) with some exceptions
				Choice or	Overall, a significantly greater proportion of patients preferred Genuair (73.7%) than
1	Forced	randomized			
Vogelmeier	Forced	randomized			Accuhaler (26.3%) (p<0.0001), with similar proportions of patients preferring Genuair
Vogelmeier 2016	choice:	controlled		proportion of	Accuhaler (26.3%) (p<0.0001), with similar proportions of patients preferring Genuair over Accuhaler for each of the device attributes assessed (all p<0.0001). The willingness
0				proportion of choice	over Accuhaler for each of the device attributes assessed (all p<0.0001). The willingness of patients to continue using each device was greater for Genuair (78.6%) than
2016	choice: inhaler	controlled trial	933	proportion of choice Mean (SD)	over Accuhaler for each of the device attributes assessed (all p<0.0001). The willingness of patients to continue using each device was greater for Genuair (78.6%) than COPD Intubation not needed 53.9 (19.8)
2016 Wildman	choice: inhaler VAS, forced	controlled trial	933 752 COPD	proportion of choice Mean (SD)	over Accuhaler for each of the device attributes assessed (all p<0.0001). The willingness of patients to continue using each device was greater for Genuair (78.6%) than
2016	choice: inhaler VAS, forced choice:	controlled trial	933 752 COPD (832 in	proportion of choice Mean (SD)	over Accuhaler for each of the device attributes assessed (all p<0.0001). The willingness of patients to continue using each device was greater for Genuair (78.6%) than COPD Intubation not needed 53.9 (19.8)
2016 Wildman	choice: inhaler VAS, forced choice: treatment	controlled trial Cohort study	933 752 COPD	proportion of choice Mean (SD) Median (IQR) Choice or proportion of	over Accuhaler for each of the device attributes assessed (all p<0.0001). The willingness of patients to continue using each device was greater for Genuair (78.6%) than COPD Intubation not needed 53.9 (19.8) COPD Intubation not needed 50 (40, 66) COPD Intubation not needed 52.3 (32.5) COPD Intubation not needed 62 (36. 74)
2016 Wildman	choice: inhaler VAS, forced choice: treatment Forced	controlled trial Cohort study Trial, non-	933 752 COPD (832 in total)	proportion of choice Mean (SD) Median (IQR) Choice or proportion of Choice or	over Accuhaler for each of the device attributes assessed (all p<0.0001). The willingness of patients to continue using each device was greater for Genuair (78.6%) than COPD Intubation not needed 53.9 (19.8) COPD Intubation not needed 50 (40, 66) COPD Intubation not needed 52.3 (32.5) COPD Intubation not needed 62 (36. 74) MV choices after the decision aid
2016 Wildman 2009	choice: inhaler VAS, forced choice: treatment	controlled trial Cohort study	933 752 COPD (832 in total)	proportion of choice Mean (SD) Median (IQR) Choice or proportion of proportion of	over Accuhaler for each of the device attributes assessed (all p<0.0001). The willingness of patients to continue using each device was greater for Genuair (78.6%) than COPD Intubation not needed 53.9 (19.8) COPD Intubation not needed 50 (40, 66) COPD Intubation not needed 52.3 (32.5) COPD Intubation not needed 62 (36.74) MV choices after the decision aid After reviewing the decision aid, 31 participants (94%) reported that they had reached a
2016 Wildman	choice: inhaler VAS, forced choice: treatment Forced	controlled trial Cohort study Trial, non-	933 752 COPD (832 in total)	proportion of choice Mean (SD) Median (IQR) Choice or proportion of proportion of	over Accuhaler for each of the device attributes assessed (all p<0.0001). The willingness of patients to continue using each device was greater for Genuair (78.6%) than COPD Intubation not needed 53.9 (19.8) COPD Intubation not needed 50 (40, 66) COPD Intubation not needed 52.3 (32.5) COPD Intubation not needed 62 (36. 74) MV choices after the decision aid
2016 Wildman 2009	choice: inhaler VAS, forced choice: treatment Forced choice:	controlled trial Cohort study Trial, non- randomized or non- controlled	933 752 COPD (832 in total)	proportion of choice Mean (SD) Median (IQR) Choice or proportion of choice Median (IQR)	over Accuhaler for each of the device attributes assessed (all p<0.0001). The willingness of patients to continue using each device was greater for Genuair (78.6%) than COPD Intubation not needed 53.9 (19.8) COPD Intubation not needed 50 (40, 66) COPD Intubation not needed 52.3 (32.5) COPD Intubation not needed 62 (36. 74) MV choices after the decision aid After reviewing the decision aid, 31 participants (94%) reported that they had reached a decision about whether they personally would accept or forego MV in the event of a serious exacerbation: only two individuals remained completely uncertain. Of those
2016 Wildman 2009	choice: inhaler VAS, forced choice: treatment Forced choice: treatment, importance	controlled trial Cohort study Trial, non- randomized or non-	933 752 COPD (832 in total)	proportion of choice Mean (SD) Median (IQR) Choice or proportion of choice Median (IOR)	over Accuhaler for each of the device attributes assessed (all p<0.0001). The willingness of patients to continue using each device was greater for Genuair (78.6%) than COPD Intubation not needed 53.9 (19.8) COPD Intubation not needed 50 (40, 66) COPD Intubation not needed 52.3 (32.5) COPD Intubation not needed 62 (36. 74) MV choices after the decision aid After reviewing the decision aid, 31 participants (94%) reported that they had reached a decision about whether they personally would accept or forego MV in the event of a serious exacerbation: only two individuals remained completely uncertain. Of those Preference for Accuhaler
2016 Wildman 2009 Wilson 2005	choice: inhaler VAS, forced choice: treatment Forced choice: treatment, importance Forced	controlled trial Cohort study Trial, non- randomized or non- controlled	933 752 COPD (832 in total) 33	proportion of choice Mean (SD) Median (IQR) Choice or proportion of choice Median (IQR)	over Accuhaler for each of the device attributes assessed (all p<0.0001). The willingness of patients to continue using each device was greater for Genuair (78.6%) than COPD Intubation not needed 53.9 (19.8) COPD Intubation not needed 50 (40, 66) COPD Intubation not needed 52.3 (32.5) COPD Intubation not needed 62 (36. 74) MV choices after the decision aid After reviewing the decision aid, 31 participants (94%) reported that they had reached a decision about whether they personally would accept or forego MV in the event of a serious exacerbation: only two individuals remained completely uncertain. Of those
2016 Wildman 2009	choice: inhaler VAS, forced choice: treatment Forced choice: treatment, importance Forced	controlled trial Cohort study Trial, non- randomized or non- controlled Randomize	933 752 COPD (832 in total) 33	proportion of choice Mean (SD) Median (IQR) Choice or proportion of choice Median (IQR) Ranking	over Accuhaler for each of the device attributes assessed (all p<0.0001). The willingness of patients to continue using each device was greater for Genuair (78.6%) than COPD Intubation not needed 53.9 (19.8) COPD Intubation not needed 50 (40, 66) COPD Intubation not needed 52.3 (32.5) COPD Intubation not needed 62 (36. 74) MV choices after the decision aid After reviewing the decision aid, 31 participants (94%) reported that they had reached a decision about whether they personally would accept or forego MV in the event of a serious exacerbation: only two individuals remained completely uncertain. Of those Preference for Accuhaler

Yun Kirby 2016	choice:	Cross-over study	287	Choice or proportion of choice	Inhaler attribute 1: size of the numbers on the dose counter (primary endpoint) 193 patients (68%) preferred ELLIPTA; 57 individuals (20%) preferred DISKUS; 35 participants (12%) expressed no preferences between the treatment options. Inhaler attribute 2: number of steps to take the COPD medication. 190 patients (67%)
-------------------	---------	---------------------	-----	--------------------------------------	--